InterPAD - DETAILS

rosiglitazone, 122320-73-4, Avandia, Rosiglizole, 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione, Brl-49653, Brl 49653, Rezult, Gaudil, Rosvel, BRL49653, TDZ 01, rosiglitazona, rosiglitazonum, Avandamet, Avandaryl, rosiglitazone (Avandia), DTXSID7037131, C18H19N3O3S, CHEBI:50122, UNII-05V02F2KDG, NSC-758698, 05V02F2KDG, TDZ-01, HSDB 7555, 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, MFCD00871760, Rosigilitazone, 2,4-thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate, DTXCID5017131, 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, Rosiglitazone (INN), NSC 758698, NCGC00095124-01, BRL 49653C, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione, 5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione, ROSIGLITAZONE [INN], 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione, ROSIGLITAZONE (IARC), ROSIGLITAZONE [IARC], ROSIGLITAZONE (MART.), ROSIGLITAZONE [MART.], 5-[4-[2-[Methyl(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione, Rosiglitazone [INN:BAN], 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, 5-(4-(2-(N-METHYL-N-(2-PYRIDINYL)AMINO)ETHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE, CAS-122320-73-4, SR-01000763023, Rosiglitazon, Rosigltazone, Rosi, Rosiglitazone base, 5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)-1,3-thiazolidine-2,4-dione, 5-[4-[2-[N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, RGZ, Gaudil (TN), Rosiglitazone- Bio-X, Spectrum_001703, 1217260-35-9, Spectrum2_001241, Spectrum3_000997, Spectrum4_001125, Spectrum5_001464, ROSIGLITAZONE [MI], SCHEMBL5169, ROSIGLITAZONE [HSDB], BSPBio_002693, KBioGR_001609, KBioSS_002183, ROSIGLITAZONE [VANDF], SPECTRUM1504263, SPBio_001142, ROSIGLITAZONE [WHO-DD], GTPL1056, ROSIGLITAZONE [EMA EPAR], SCHEMBL14383595, KBio2_002183, KBio2_004751, KBio2_007319, KBio3_001913, A10BG02, Rosiglitazone, >=98% (HPLC), HMS1922J11, HMS2094O13, HMS3649G08, HMS3656K16, HMS3744M11, HMS3871L03, HMS3884N08, Pharmakon1600-01504263, BCP03047, Tox21_111434, BDBM50030474, CCG-39102, HB2556, NSC758698, STL350047, AKOS015894872, O-De-Me, 2-O-B-D-galactopyranoside, Tox21_111434_1, AC-3459, BCP9000017, CS-1088, DB00412, SB17326, NCGC00095124-02, NCGC00095124-03, NCGC00095124-04, NCGC00095124-05, NCGC00095124-06, NCGC00095124-08, BR164372, HY-17386, SY031184, BCP0726000232, NS00008920, R0106, S2556, SW197573-6, 6P-065, D08491, S00306, AB00698473-15, AB00698473-17, AB00698473-18, AB00698473-19, AB00698473_20, AB00698473_21, AB00698473_22, AB00698473_23, Q424771, Q-201681, SR-01000763023-5, SR-01000763023-6, BRD-A97437073-001-02-3, BRD-A97437073-001-03-1, BRD-A97437073-001-04-9, SR-01000763023-12, (+-)-5-(p-(2-(methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione, (RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion, 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)-benzyl)thiazolidine-2,4-dione, 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4dione, IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin), (+/-)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione, 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI), 5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-2,4-thiazolidinedione, 5-[[4-[2-(Methyl-2-pyridinylamino)e thoxy]phenyl]methyl]-2,4-thiazolidinedione, 5-[[4-[2-(methyl-pyridin-2-ylamino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione, 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]phenyl methyl]thiazolidine-2,4-dione

Name	Rosiglitazone
PubChem CID	77999
Molecular Weight	357.4g/mol
Synonyms	rosiglitazone, 122320-73-4, Avandia, Rosiglizole, 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione, Brl-49653, Brl 49653, Rezult, Gaudil, Rosvel, BRL49653, TDZ 01, rosiglitazona, rosiglitazonum, Avandamet, Avandaryl, rosiglitazone (Avandia), DTXSID7037131, C18H19N3O3S, CHEBI:50122, UNII-05V02F2KDG, NSC-758698, 05V02F2KDG, TDZ-01, HSDB 7555, 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, MFCD00871760, Rosigilitazone, 2,4-thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate, DTXCID5017131, 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, Rosiglitazone (INN), NSC 758698, NCGC00095124-01, BRL 49653C, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione, 5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione, ROSIGLITAZONE [INN], 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione, ROSIGLITAZONE (IARC), ROSIGLITAZONE [IARC], ROSIGLITAZONE (MART.), ROSIGLITAZONE [MART.], 5-[4-[2-[Methyl(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione, Rosiglitazone [INN:BAN], 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, 5-(4-(2-(N-METHYL-N-(2-PYRIDINYL)AMINO)ETHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE, CAS-122320-73-4, SR-01000763023, Rosiglitazon, Rosigltazone, Rosi, Rosiglitazone base, 5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)-1,3-thiazolidine-2,4-dione, 5-[4-[2-[N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, RGZ, Gaudil (TN), Rosiglitazone- Bio-X, Spectrum_001703, 1217260-35-9, Spectrum2_001241, Spectrum3_000997, Spectrum4_001125, Spectrum5_001464, ROSIGLITAZONE [MI], SCHEMBL5169, ROSIGLITAZONE [HSDB], BSPBio_002693, KBioGR_001609, KBioSS_002183, ROSIGLITAZONE [VANDF], SPECTRUM1504263, SPBio_001142, ROSIGLITAZONE [WHO-DD], GTPL1056, ROSIGLITAZONE [EMA EPAR], SCHEMBL14383595, KBio2_002183, KBio2_004751, KBio2_007319, KBio3_001913, A10BG02, Rosiglitazone, >=98% (HPLC), HMS1922J11, HMS2094O13, HMS3649G08, HMS3656K16, HMS3744M11, HMS3871L03, HMS3884N08, Pharmakon1600-01504263, BCP03047, Tox21_111434, BDBM50030474, CCG-39102, HB2556, NSC758698, STL350047, AKOS015894872, O-De-Me, 2-O-B-D-galactopyranoside, Tox21_111434_1, AC-3459, BCP9000017, CS-1088, DB00412, SB17326, NCGC00095124-02, NCGC00095124-03, NCGC00095124-04, NCGC00095124-05, NCGC00095124-06, NCGC00095124-08, BR164372, HY-17386, SY031184, BCP0726000232, NS00008920, R0106, S2556, SW197573-6, 6P-065, D08491, S00306, AB00698473-15, AB00698473-17, AB00698473-18, AB00698473-19, AB00698473_20, AB00698473_21, AB00698473_22, AB00698473_23, Q424771, Q-201681, SR-01000763023-5, SR-01000763023-6, BRD-A97437073-001-02-3, BRD-A97437073-001-03-1, BRD-A97437073-001-04-9, SR-01000763023-12, (+-)-5-(p-(2-(methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione, (RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion, 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)-benzyl)thiazolidine-2,4-dione, 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4dione, IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin), (+/-)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione, 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI), 5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-2,4-thiazolidinedione, 5-[[4-[2-(Methyl-2-pyridinylamino)e thoxy]phenyl]methyl]-2,4-thiazolidinedione, 5-[[4-[2-(methyl-pyridin-2-ylamino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione, 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]phenyl methyl]thiazolidine-2,4-dione
Drug Type	Small molecule
Formula	C₁₈H₁₉N₃O₃S
SMILES	CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3
InChI	1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
InChIKey	YASAKCUCGLMORW-UHFFFAOYSA-N
CAS Number	122320-73-4
ChEMBL ID	CHEMBL121
ChEBI ID	CHEBI:50122
TTD ID	D0K5ER
Drug Bank ID	DB00412
KEGG ID	D08491
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Honokiol, Rosiglitazone
Partner Name	Honokiol
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CCNE1	hsa898
	Up-regulation	Expression	CDKN1A	hsa1026
	Down-regulation	Expression	RB1	hsa5925
In Vitro Model	Mahlavu	Hepatocellular carcinoma	Homo sapiens (Human)	CVCL_0405
In Vitro Model	SK-HEP-1	Liver and intrahepatic bile duct epithelial neoplasm	Homo sapiens (Human)	CVCL_0525
Result	Honokiol combined with rosiglitazone showed more effective growth inhibition in hepatoma cells mediated through the regulation of G0/G1 phase-related proteins p21, cyclin D1, cyclin E1, and Rb and cell cycle progression

Pair Name	Niacinamide, Rosiglitazone
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.

No.	Title	Href
1	DDInter: an online drug-drug interaction database towards improving clinical decision-making and patient safety. Nucleic Acids Res. 2022;50(D1):D1200-D1207. doi:10.1093/nar/gkab880	`Click`
2	Combined effect of honokiol and rosiglitazone on cell growth inhibition through enhanced G0/G1 phase arrest in hepatoma cells. J Chin Med Assoc. 2016 Aug;79(8):415-21. doi: 10.1016/j.jcma.2016.03.003.	`Click`